home / stock / nvs / nvs articles

NVS Articles, Novartis AG - From 12/19/23

Stock Information
Company Name: Novartis AG
Stock Symbol: NVS
Market: NYSE
Website: novartis.com
Menu
NVS NVS Quote NVS Short NVS News NVS Articles NVS Message Board
Get NVS Alerts

News, Short Squeeze, Breakout and More Instantly...
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug | Benzinga

Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivot...
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients | Benzinga

The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhib...

Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease | Benzinga

Novartis AG (NYSE: NVS) announced topline results from the six-month, double-blind period of the Phase 3 APPEAR-C3G study of iptacop...

Novartis' Rare Blood Disorder Therapy Scores FDA Approval | Benzinga

The FDA approved Novartis AG's (NYSE: NVS) Fabhalta (iptacopan) as the first oral monotherapy for adult patients with paroxysmal...
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies | Benzinga

Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive ly...

Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off | Benzinga

Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovas...

Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study | Benzinga

Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patient...
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week | Benzinga

The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More | Benzinga

The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multipl...

Stocks Surge Ahead Of Microsoft, Alphabet Earnings, Bitcoin Eyes Sixth Day Of Gains: What's Driving Markets Tuesday? | Benzinga

Stocks enjoyed a positive midday trading session in New York, with all major indices in the green. Additionally, nine out of 11 S&P 500 sectors...
Previous 10 Next 10